Recombinant Antibody Production with Guaranteed Stability

Recombinant monoclonal antibodies were previously cloned into mammalian expression vectors, such as pcDNA3.1 and transiently transfected into producer cells such as HEK293 or CHO cells for short-term expression. Transient transfection, however, lacks the ability to make stable cell lines that can continuously secrete IgG molecules over many generations of cell culture.

BiCell Scientific has found that an equal number of light chain to heavy chain is essential for correct folding of heavy chain and secretion of antibody with thermal stability. BiCell Scientific’s recombinant antibody production service harnesses the advantageous lentiviral transduction ability to simultaneously express IgG heavy chain and light chain at a molecular ratio of 1:1 in three types of producer cells: B-cell hybridoma, HEK293 suspension cell and CHO suspension cell. The resultant stably transfected cells can produce recombinant antibodies at a similar level to native B cell-myeloma fused hybridomas. The resultant recombinant antibodies undergo similar assembly and modification processes to native antibodies in the endoplasmic reticulum, that is crucial to obtain antibody preparations with low contents of aggregates.

BiCell Scientific’s Recombinant Antibody Production Service can be used in conjunction with BiCell Scientific’s Bioreactor Scale-up Service of Antibody Production in Hybridoma (Cat No: BCMCHY) or Bioreactor Scale-up Service of Antibody Production in HEK293 or CHO Suspension (Cat No: BCHKCO) to manufacture up to 1 g of recombinant antibodies.